Renal Disorder Associated With Type II Diabetes Mellitus
Conditions
Brief summary
To investigate the effect of co existance of diabetes mellitus and chronic kidney disease on basic coagulation profile in comparison with diabetic patients with normal kidney function and non diabetic patients with chronic kidney disease
Detailed description
We will study impact of type 2 diabetes mellitus on basic coagulation profile and platelet indices among patients with chronic kidney disease
Interventions
DIAGNOSTIC_TESTHematologic tests for patients with diabetes mellitus and chronic kidney disease
Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
Sponsors
Sohag University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diabetes mellitus with and without chronic kidney disease Patients with chronic kidney disease without diabetes mellitus
Exclusion criteria
* any situation influence on basic coagulation profile and platelet indices other than diabetes mellitus and chronic kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin time | 1 day | We will include 150 patients and classify them into 3 groups each one consists of 50 patients First group those patients with diabetes mellitus only Second group those patients with chronic kidney disease only Third group those patients with combined diabetes mellitus type 2 and chronic kidney disease not on hemodialysis First we will measure prothrombin time |
| Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin concentration | 1 day | We will include 150 patients classified into 3 groups as previous Second measure is prothrombin concentration |
| Estimate risk of thrombosis or bleeding for the 3 study groups by INR | 1 day | We will include 150 patients as previous Third measure is INR ( international normalised ratio ) |
| Estimate risk of thrombosis or bleeding for the 3 study groups by partial thromboplastin time | 1 day | We will include 150 patients as previous Fourth measure is partial thromboplastin time |
| Estimate risk of thrombosis or bleeding for the 3 study groups by serum fibrinogen | 1 day | We will include 150 patients as previous Fifth measure is serum fibrinogen level in the 3 groups |
| Estimate risk of thrombosis or bleeding for the 3 study groups by mean platelet volume | 1 day | We will include 150 patients as previous Sixth measure is mean platelet volume in the 3 groups |
| Estimate risk of thrombosis or bleeding for the 3 study groups by platelet distribution width | 1 day | We will include 150 patients as previous Seventh measure is platelet distribution width for the 3 groups |
| Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit | 1 day | We will include 150 patients as previous Eighth measure is plateletcrit of the 3 study groups |
Countries
Egypt
Outcome results
None listed